European approach to the treatment of malignant melanoma

Current Opinion in Oncology

Volumn 14, Issue 2, 2002, Pages 205-211

  Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; DACARBAZINE; TAMOXIFEN; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; EUROPE; HUMAN; LIMB PERFUSION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; EUROPE; HUMANS; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0036128239     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200203000-00011     Document Type: Review

References (62)

1. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
2. Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm
3. Wide versus narrow surgical excision in thin (<2mm) stage I primary cutaneous malignant melanoma: Long term results of a French multicentric prospective randomized trial on 319 patients
4. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm
5. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): Results of a multi-institutional randomized surgical trial
6. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas
7. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma
8. Surgical management of malignant melanoma
9. Lymph node metastases: Indicators, but not governors of survival
10. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs
11. A prospective randomized study of the efficacy of routine elective lymphadenopathy in management of malignant melanoma: Preliminary results
12. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
13. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) trial
14. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial
15. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping
16. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma
17. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
18. Treatment of melanoma in-transit metastases confined to the limb
19. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
20. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience
21. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives
22. The current EORTC Melanoma Cooperative Group adjuvant trial program on malignant melanoma: Prognosis versus efficacy, toxicity and costs
23. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
24. SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine
25. Improved survival in stage III melanoma patients with GM2 antibodies: A randomised trial of adjuvant vaccination with GM2 ganglioside
26. Adjuvant immunotherapy of malignant melanoma: Status of clinical trials at UCLA
27. Significant impact of HLA class I alleles on outcome in T3N0M0 melanoma patients treated with Melacine (MEL): An allogeneic cell lysate vaccine: Prospective analysis of Southwest Oncology Group (SWOG)-9035
28. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1648
29. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
30. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma
31. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
32. Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma
33. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801
34. Results of adjuvant interferon study in WHO melanoma programme
35. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
36. Adjuvant interferon alpha in high risk melanoma: The Scottish study
37. The European Organization for Research and Treatment of Cancer Melanoma Group Trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b
38. Aim high-adjuvant interferon in melanoma (high risk). A United Kingdom Co-ordinating Committee on Cancer Research (IKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alfa-2a in high risk resected malignant melanoma
39. Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma
40. Interferon as an adjuvant treatment for melanoma: Registered but not indicated
41. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
42. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
43. Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials
44. Role of interferon-alpha in malignant melanoma remains to be determined
45. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: A randomized phase III trial
46. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
47. Randomized double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
48. Phase III clinical trial of the combination of cisplatin, dacarbazide and carmustine with or without tamoxifen in patients with advanced malignant melanoma
49. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
50. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
51. Interferon-alpha 2a does not improve response or survival when combined with dacarbazide in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial
52. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
53. Phase III trial of dacarbazine versus dacarbazide with interferon alpha2b versus dacarbazide with tamoxifen versus dacarbazide with interferon alpha2b with tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology study
54. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
55. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
56. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organisation for Research and Treatment of Cancer Melanoma Cooperative Group
57. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin-2 in patients with metastatic melanoma
58. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Centre le Cancer Multicenter, parallel study
59. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
60. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2B (INF) versus CVD in patients (pts) with metastatic melanoma
61. Dacarbazine, cisplatin and IFN-a with or without IL-2 in advanced melanoma (EORTC trial 18951)
62. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: A randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)